Cognitive functioning in first episode psychosis. Gender differences and relation with clinical variables. Issue 6 (23rd December 2020)

• Record Type: Journal Article
• Authors: Vila‐Badia, Regina; Del Cacho, Núria; Butjosa, Anna; Ochoa, Susana; Serra‐Arumí, Clara; Esteban‐Sanjusto, Marina; Pardo, Marta; Dolz, Montserrat; Casado‐Ortega, Ariadna; Coromina, Marta; Usall, Judith
• Is Part Of: Early intervention in psychiatry. Volume 15:Issue 6(2021)
• Page Start: 1667
• Page End: 1676
• Publication Date: 2020-12-23
• Subjects: cognition -- first‐episode psychoses -- gender -- symptoms; Mental health -- Periodicals; Psychiatry -- Periodicals; Psychiatry -- Research -- Periodicals; Mental illness -- Prevention -- Research -- Periodicals; Mental illness -- Treatment -- Research -- Periodicals; 616.89
• DOI: 10.1111/eip.13110
• Languages: English
• ISSNs: 1751-7885

Abstract

Abstract: Aims: to study the differences in cognitive functioning in patients and controls. In addition, study the influence of symptoms, cannabis consumption, chlorpromazine doses, DUP and IQ in cognitive performance in patients, both in the total sample and divided by gender. Methods: 70 first episode psychosis patients and 63 healthy controls (HC) participated in the study and were assessed with the MATRICS battery and the Vocabulary subtest of WAIS‐IV. Symptoms in FEP patients were evaluated with the Emsley factors of the PANSS scale. Results: patients showed lower scores than controls in all cognitive domains studied. There were no significant differences between FEP men and FEP women, but we found gender differences in favour of women in processing speed, working memory and composite total scored domains in the HC group. Finally, symptoms and Chlorpromazine doses showed an influence on cognitive performance in the total FEP sample. When splitting the sample by gender, positive symptoms may be more detrimental to women's cognitive functioning, while disorganized symptoms may play the most important role in cognitive performance in men. Conclusions: patients showed worse cognitive performance in all cognitive domains compared to healthy controls. In our FEP sample, gender does not seem to influence cognitive performance measured with the MATRICS. Severity of symptoms influences positively in cognitive performance. The dose of Chlorpromazine and symptoms are influential variables to be taken into account in cognition rehabilitation programs.